Results 111 to 120 of about 41,944 (264)

Triple negative breast cancer: new perspectives for targeted therapies [PDF]

, 2015
Breast cancer is a heterogeneous disease, encompassing a large number of entities showing different morphological features and having clinical behaviors.
Caruso, Davide, Frati, Luigi, Minozzi, Marina, Papa, Anselmo, Rossi, Luigi, Tomao, Federica, Tomao, Silverio, Vici, Patrizia, Zaccarelli, Eleonora   +8 more
core   +1 more source

α2,3‐Sialyltransferase (ST3Gal1) regulates endometrioid‐type epithelial ovarian cancer cell migration and invasion via VEGF‐R2/JAK2/STAT3 signaling cascades

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To investigate the role of ST3 β‐galactoside α‐2,3‐sialyltransferase 1 (ST3Gal1) and vascular endothelial growth factor receptor 2 (VEGF‐R2) in endometrioid‐type epithelial ovarian cancer (E‐OC) because aberrant α2,3‐sialylation mediated by ST3Gal1 and VEGF‐R2‐related angiogenesis is linked with tumor progression. Methods ST3Gal1 and
Wei‐Ting Chao, Chia‐Hao Liu, Szu‐Ting Yang, Chen‐Hao Lin, Liang‐Wei Wang, Peng‐Hui Wang   +5 more
wiley   +1 more source

The poly (ADP-ribose) polymerase inhibitor olaparib attenuates established pulmonary fibrosis in a large animal model

BMC Pulmonary Medicine
Background Poly (ADP‒ribose) polymerase (PARP) is a constitutive enzyme involved in regulating various biological processes in health and disease. In the present study, we investigated the role of PARP1 in pulmonary fibrosis and assessed the efficacy of ...
Habtamu B. Derseh, Andrew N. Davies, Alarna Young, Sylvie Bischof, Joseph Pelle, David Rudd, Michelle McIntosh, David Piedrafita, Robert J. Bischof   +8 more
doaj   +1 more source

The PARP inhibitor AZD2461 provides insights into the role of PARP3 inhibition for both synthetic lethality and tolerability with chemotherapy in preclinical models [PDF]

, 2016
The PARP inhibitor AZD2461 was developed as a next-generation agent following olaparib, the first PARP inhibitor approved for cancer therapy. In BRCA1-deficient mouse models, olaparib resistance predominantly involves overexpression of P-glycoprotein,so ...
Aaron N. Cranston, Alan Lau, Attilla Ting, Bastiaan Evers, Charlotte Knights, David Rudge, Henry Brown, Janneke E. Jaspers, Jos Jonkers, Keith W. Caldecott, Lenka Oplustil O'Connor, Louise Jones, Marina Pajic, Mark J. O'Connor, Niall M.B. Martin, Rajesh Odedra, Robert H. Bradbury, Stuart L. Rulten, Sven Rottenberg   +18 more
core   +1 more source

The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer

Nature
PARTNER is a prospective, phase II–III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer1,2, who were germline BRCA1 and BRCA2 wild type3. Here we report the results of the trial.
J.E. Abraham, Karen Pinilla, A. Dayimu, L. Grybowicz, Nikolaos Demiris, C. Harvey, Lynsey M. Drewett, Rebecca Lucey, Alexander Fulton, Anne N Roberts, Joanna R. Worley, A. Chhabra, Wendi Qian, A. Vallier, Richard Hardy, S. Chan, Tamas Hickish, Devashish Tripathi, R. Venkitaraman, M. Persic, Shahzeena Aslam, Daniel Glassman, Sanjay Raj, A. Borley, J.P. Braybrooke, Stephanie Sutherland, Emma Staples, Lucy C Scott, M. Davies, C. A. Palmer, Margaret Moody, Mark J. Churn, Jacqueline C. Newby, Mukesh B Mukesh, Amitabha Chakrabarti, R. Roylance, Philip C. Schouten, N. Levitt, K. McAdam, A. Armstrong, E. Copson, E. McMurtry, M. Tischkowitz, E. Provenzano, Helena M Earl   +44 more
semanticscholar   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

iNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid, Weirong Fan, Farah Nazir, Yixiang Xing, Tengchuan Jin   +4 more
wiley   +1 more source

ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells [PDF]

, 2016
BACKGROUND: Clinical response to chemotherapy for ovarian cancer is frequently compromised by the development of drug-resistant disease. The underlying molecular mechanisms and implications for prescription of routinely prescribed chemotherapy drugs are ...
A Eva, A Sonnenblick, A Tutt, AA Ahmed, AG Patel, Alison L Scott, AM Oza, AM Patch, Anne-Louise Gannon, Aparajitha Vaidyanathan, AR Safa, AT Fojo, B Norquist, BI Sikic, CK Ingemarsdotter, D Lawlor, DA Zajchowski, DW Shen, E Dean, EM Swisher, F Hyafil, F Micci, G Konecny, G Smith, G Wurzer, G Xu, Gillian Smith, GK Smyth, H Chang, H Farmer, H Green, H Parekh, H Thomas, HE Bryant, HS Kim, IE Dumitriu, J Tapper, J Wesierska-Gadek, JD Allen, JE Jaspers, JE Jaspers, JF Liu, JM Lee, K Partheen, L Liu, LY Tao, Lynne Sawers, M Boesch, M Rouleau, M Yun, Michelle J Ferguson, MM Cornwell, MN Fransson, MW Audeh, N Johnson, N Syed, Probir Chakravarty, R Cincinelli, RF Ozols, RJ Kathawala, RJ Kelly, RJ Kelly, RT Penson, RW Martin, S Arao, S Durmus, S Marsh, S Rottenberg, S Vaughan, SE Johnatty, SL Edwards, SP Langdon, Susan E Bray, T Krech, T Mosmann, TA Holzmayer, V Materna, W Sakai, X Yang, YC Wang   +79 more
core   +3 more sources

Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer

Clinical Cancer Research
Purpose: We explored the efficacy of PARP inhibition with or without programmed death ligand-1 (PD-L1) blockade as chemotherapy-free maintenance therapy for advanced triple-negative breast cancer (aTNBC) sensitive to platinum-based chemotherapy. Patients
T. Tan, S. Sammons, Young-Hyuck Im, Lilin She, K. Mundy, R. Bigelow, T. Traina, Carey K. Anders, J. Yeong, Ezequiel Renzulli, Sung-Bae Kim, R. Dent   +11 more
semanticscholar   +1 more source

Deubiquitinase USP38 Stabilizes PLK1 Expression to Boost DNA Damage Repair in Ovarian Cancer

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Ovarian cancer (OC) is one of the most prevalent and severe gynecological malignant tumors. DNA damage repair (DDR) is essential in maintaining genome stability. This study aims to investigate the effects and mechanisms of USP38 and PLK1 on DNA damage repair and malignant behavior in OC cells.
Yuan Ma, Ying Li, Kai‐Li Li
wiley   +1 more source

BMN673 sensitizes rhabdomyosarcoma tumors to irradiation in vivo [PDF]

, 2020
Bone and soft tissue sarcomas are mesenchymal tumors that occur rarely in adults, representing only 1% of total malignancies, but comprise up to 13% of malignant tumors in children.1 Rhabdomyosarcoma, a soft tissue sarcoma that commonly affects children,
Jacob, Connor
core